Monitoring treatment with 5-Azacitidine by flow cytometry predicts duration of hematological response in patients with myelodysplastic syndrome.
Ann Hematol. 2021 Jan 9. doi: 10.1007/s00277-021-04411-4. Online ahead of print.
Ann Hematol. 2021.
PMID: 33423077